An Initial Study of Lithium in Patients With Medullary Thyroid Cancer
Primary objective is to evaluate the tumor response rate of patients with MTC treated with Lithium carbonate
Medullary Thyroid Cancer
DRUG: Lithium carbonate
Tumor Response Rate Measured by the Response Evaluation Criteria in Solid Tumors (RECIST), 1 year
Primary objective is to evaluate the tumor response rate of patients with MTC treated with Lithium carbonate